In a phase 3 trial, #culmerciclib plus #fulvestrant improved PFS and response rates versus fulvestrant alone in pretreated #HRPositive, #HER2Negative advanced #BreastCancer, supporting dual CDK2/4/6 targeting to overcome resistance.

#OpenAccess in #STTT: doi.org/10.1038/s413...

We are leading a new study to evaluate the safety & effectiveness of #Avutometinib (#Avmapki®) with #abemaciclib (Verzenio®) + #fulvestrant (Faslodex®) in metastatic HR+/HER2- #BreastCancer.

To learn more call 877-338-7425 or visit dana-farber.org/clinical-tri...

A phase 3 #ClinicalTrial evaluating the efficacy of #Culmerciclib + #Fulvestrant in HR-positive, HER2-negative advanced #BreastCancer demonstrated improved progression-free survival and a manageable safety profile.

#STTT #OpenAccess: doi.org/10.1038/s413...

E2 Levels in Women With HR+ Breast Cancer on Fulvestrant Prognostic of Treatment Efficacy - Oncology Nurse Advisor Estradiol level appeared to indicate prognosis for PFS in women with HR-positive advanced breast cancer receiving first- or second-line fulvestrant.

Monitoring E2 levels in women with HR+ #breastcancer during treatment with #fulvestrant can help clinicians better assess patients’ E2 status and treatment’s efficacy.

https://bit.ly/3NCZSYW

#bcsm

#Culmerciclib combined with #fulvestrant significantly improved #ProgressionFreeSurvival and response rate in pretreated HR‑positive, #HER2‑negative advanced #BreastCancer, supporting combined CDK2/4/6 blockade as a promising therapeutic strategy.

#STTT: doi.org/10.1038/s413...

A randomized, double-blind, phase 3 #ClinicalTrial evaluating the efficacy of #Culmerciclib + #Fulvestrant in HR-positive, HER2-negative #AdvancedBreastCancer showed improved progression-free survival & tolerable safety.

#STTT #OpenAccess: doi.org/10.1038/s413...

Feeling blessed. 4 months in on my new treatment plan of #fulvestrant and #capivasertib. Recent scans show no progression. Generic Zofran & Lotomil plus Immodium have minimized nausea & diarrhea so I can be more present for my family. 90 months since #mbc diagnosis I'm still here. #cancer #bestlife

#LOBSTER trial #GBG118 for pts with #lobular #breastcancer: It investigates whether the combination of #capivasertib + #fulvestrant can achieve a stronger therapeutic effect than fulvestrant alone – aiming to reduce #recurrence risk and improve quality of life.
👉 www.gbg.de/en/trials/lo...

Erika Hamilton: Vepdegestrant Outperforms Fulvestrant in Advanced ER+HER2− Breast Cancer - OncoDaily Erika Hamilton: Vepdegestrant Outperforms Fulvestrant in Advanced ER+HER2− Breast Cancer / Breast Cancer, cancer, Erika Hamilton, OncoDaily, Oncology

Vepdegestrant Outperforms Fulvestrant in Advanced ER+HER2− Breast Cancer - Erika Hamilton

@erikahamilton9.bsky.social

oncodaily.com/insight/erik...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Vepdegestrant #Fulvestrant #BreastCancer

Shifting First-Line Strategy: Inavolisib Shows OS, PFS Gains in INAVO120 Trial | Docwire News INAVO120 shows OS benefit with inavolisib in PIK3CA-mutated HR+/HER2– aBC, raising new considerations for first-line care.

#INAVO120: Neue Hoffnung für Patientinnen mit #PIK3CA-mutiertem HR+/HER2- Brustkrebs! Auf dem #ASCO2025 stellte Prof. Sibylle Loibl die finale OS-Analyse vor: +7 Monate medianes Überleben mit #Inavolisib + #Palbociclib + #Fulvestrant in der First-Line-Therapie
www.docwirenews.com/post/shiftin...

Primary results from a phase 2a study show #Zanidatamab + #Palbociclib + #Fulvestrant is a promising chemotherapy-free option for heavily pretreated HR+/HER2+ MBC patients.

@thelancetoncol.bsky.social

#Onco404 #Cancer #Kanser #BreastCancer #ClinicalTrials #HER2 #ADC #TDXd #Healthcare #Innovation

New JCO 📰 #Abemaciclib Plus #Fulvestrant in Advanced #BreastCancer Following Progression on CDK4/6 Inhibition: Results from the postMONARCH Trial
🔓https://pubmed.ncbi.nlm.nih.gov/39693591/
✍️ @erikahamilton9.bsky.social @drsgraff.bsky.social @drsarahsammons.bsky.social @bastien-nguyen.bsky.social